Development of
Medical Imaging Systems
offering a new paradigm

Unlike in the past when focused on ex post facto treatment of diseases, today’s paradigm of medical services is changing into the precision medicine which helps with early diagnoses, provides quicker and easier treatment,
and applies individualized optimal therapies based on the patients’ genetic information. In addition, by utilizing the
electronically accumulated big data, current medical services are rapidly evolved into predictive medicine which can forecast the possibility of diseases and provide healthcare services accordingly.

In response to the paradigm of medical services accelerated through the Fourth Industrial Revolution, we, here at
Endolfin, are going to develop and provide the innovative medical imaging systems. These systems not only allow
individuals to practise healthcare, have personalized therapeutic support utillizing big data, but also provide medical
professionals with accurate analytics and results, so that It will double the efficiency of treatment and healthcare.

Participation in
Global Value Chains
through innovation

Endolfin introduces innovative and creative ideas and commercializes them immediately. This is how we are bringing
about a newer innovation far faster than ever. We carry forward these innovative efforts in two ways; commercialization of self-developed technologies and NRDO (No Research & Development Only).

In the era of the Fourth Industrial Revolution where complex shift occurs very quickly, where technology and industry integrate and their boundaries gradually erode, Endolfin does not persist in our internal capabilities and self-developed technology, but introduces outside opinions and technologies flexibly. Therefore, we are trying to take the lead not only in domestic but global market as well through “Open Innovation” which provides innovative products and services fast and agile.
* Google has created an innovative business model called AdWords, by introducing Overture's technology. The company developed an algorithm that pays for advertising when
  users’ clicks occur with keyword search.

According to the Deloitte’s Pharma Analytics, it is confirmed that the success rate of new drug development through Open Innovation Model is 3 times higher than the existing Closed Innovation Model. (*BIO ECONOMY BRIEF(issue 48), Open Innovation and Pharmaceutical Industry, 2018(June)
Fueling creative and rapid innovation, Endolfin will break into the global diagnostic imaging medical device market where is dominated by the global healthcare enterprises in the US and Europe continent. As a K-Medical Device front-runner, we will take the lead in the Global Value Chains of diagnostic imaging medical device industry.